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Ultrasound Contrast Agent Safety
From Anecdote to Evidence*
Michael L. Main, MD
Kansas City, MissouriIn October 2007, the U.S. Food and Drug Admin-
istration (FDA) mandated significant revisions to
product labeling for the commercially available
perflutren-containing ultrasound contrast agents
(UCA) Definity (perflutren lipid microsphere in-
jectable suspension, Lantheus Medical Imaging,
North Billerica, Massachusetts) and Optison (per-
flutren protein type A microspheres for injectable
See page 1048
suspension, GE Healthcare, Buckinghamshire,
United Kingdom) after spontaneous reports of 4
patient deaths and approximately 190 “severe car-
diopulmonary reactions” occurring in close tempo-
ral relationship to UCA administration (1). This
3-part labeling revision included a new “black box”
warning (advising of the potential for “serious
cardiopulmonary reactions”) and multiple new dis-
ease state contraindications to UCA use, including
acute myocardial infarction (MI) or acute coronary
syndromes, worsening or decompensated heart fail-
ure, serious ventricular arrhythmias or patients at
high risk for arrhythmias based on QT interval
prolongation, as well as respiratory failure, severe
emphysema, pulmonary emboli, or other conditions
that may cause pulmonary hypertension. Finally,
the FDA also required a blanket 30-min monitor-
ing period after UCA injection for all patients,
including ambulatory outpatients (1).
Immediate response from the echocardiography
community was strongly critical of the FDA action,
*Editorials published in JACC: Cardiovascular Imaging reflect the views of
the authors and do not necessarily represent the views of JACC: Cardio-
vascular Imaging or the American College of Cardiology.
From Saint Luke’s Mid America Heart Institute, Kansas City, Missouri.
Dr. Main serves as a principal investigator for clinical trials sponsored by
Lantheus Medical Imaging and GE Healthcare.with clinicians charging that the agency had ig-
nored the previously published safety profile of
UCAs in clinical trials at doses exceeding those
used in clinical practice, the anecdotal nature of
post-marketing safety reports, and the likelihood
that deaths and poor outcomes associated with
UCA use were in fact “pseudocomplications” (death
or complication due to progression of the underly-
ing disease state rather than diagnostic testing or
therapeutic intervention) (2,3). Critics also noted
the greater potential risks associated with alterna-
tive testing procedures such as transesophageal
echocardiography and radionuclide ventriculogra-
phy (which would now be necessary in many pa-
tients), the hazards of misdiagnosis or missed diag-
nosis (due to poor-quality studies without contrast),
and the fact that patients with disease state contra-
indications, including many hospitalized in inten-
sive care units, were the very patients most in need
of, and likely to derive significant benefit from,
contrast-enhanced echocardiography (2,3).
In July 2008, after intense advocacy by physician
experts, publication of exculpatory safety data in
hospitalized patients (4), and a better understand-
ing of contrast-enhanced echocardiography efficacy,
the FDA partially relaxed product labeling for both
Optison and Definity (5). Although a black box
warning still exists, the October 2007 disease state
contraindications have been replaced by warnings.
Additionally, the 30-min monitoring period after
injection now applies only to patients with pulmo-
nary hypertension (the severity of which is not
defined) and patients with “unstable cardiopulmo-
nary conditions” (who presumably would be hospi-
talized in intensive care units and subject to con-
tinuous rhythm and hemodynamic monitoring) (5).
Since early 2008, multiple UCA safety studies
have been published in the peer-reviewed litera-
ture (4,6–12). These studies (with experience in
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1058200,000 patients receiving UCAs) have estab-
ished the relative safety of Optison and Definity in
wide range of clinical environments, including
ospitalized patients (4,6,7–11), ambulatory outpa-
ients (7–12), and, in a more limited sense, stress
chocardiography (7–12). Although the FDA has
ot expressly approved UCAs for use in stress
chocardiography (and UCAs would not have been
ontraindicated in most patients undergoing stress
chocardiography even under the original FDA
abeling changes in October 2007), safety of UCAs
or this indication is an important issue. Marketing
ata for the calendar year 2008 indicates that
ontrast agents were used in approximately 3.2% of
tress echocardiographic studies in the U.S. (vs.
nly 0.4% of resting studies, with both percentages
ramatically lower in comparison with 2007 and
revious years) (Arlington Medical Resources Im-
ging Market Guide [USA Edition], unpublished
ata, 2005–2008), the American Society of Echo-
ardiography recommends use of UCAs for the
tress echocardiography indication in “difficult to
mage patients presenting for echocardiography
ith reduced image quality” (13), and the recently
ublished Stress Echocardiography Appropriate-
ess Criteria find selective use of contrast (when 2
r more contiguous segments are not seen on
oncontrast images) both acceptable and reasonable
with an appropriateness score of 8) (14).
In this issue of iJACC, Abdelmoneim et al. (15)
xtend the growing body of UCA safety literature
ith a retrospective study in patients undergoing
tress echocardiography at the Mayo Clinic in
ochester, Minnesota, between November 2003
nd December 2007. A total of 26,774 patients
ndergoing either exercise or pharmacologic stress
chocardiography comprised the study population,
ncluding 10,792 patients who received an ultra-
ound contrast agent (86% Definity and 14% Op-
ison) and underwent either exercise (n  4,276) or
obutamine (n  6,516) stress echocardiography.
nd points included all-cause mortality or MI over
he short term (72 h) and intermediate term (30
ays), as well as long-term all-cause mortality or MI
n a subgroup of propensity-matched patients (with
ollow-up extending to 4.5 years). Patients receiving
UCA were older and sicker (with a significantly
igher prevalence of diabetes mellitus, systemic
ypertension, and symptomatic coronary artery dis-
ase in the contrast cohort) and more frequently
nderwent dobutamine echocardiography, presum-
bly due to inability to exercise. Despite these
igher risk features, there was no increase in any of ihe primary study end points in patients receiving a
CA. These results are reassuring and corroborate
reviously published data (see Table 5 in Abdelmo-
eim et al. [15]) which has established an excellent
afety profile for UCAs in now 9 large-scale post-
arketing studies (4,6–12,15).
An important observation in the present study
and consistent with data from the Hennepin
ounty database [n  16,025 contrast injections]
7] and the American Society of Echocardiography
atabase [n  78,383 contrast injections] [8]) is an
pproximate 1:10,000 incidence of acute anaphylac-
oid reaction immediately after (generally within
everal min) UCA injection. These reactions are
elieved to be secondary to a recently described
ariant of the type I hypersensitivity reaction (com-
lement activation-related pseudoallergy), and can
e life-threatening (16). This risk can be readily
itigated by early recognition of anaphylactoid
eactions and prompt treatment with an intramus-
ular injection of 0.3 mg/1:1,000 dilution of epi-
ephrine (commercially available in the U.S. as an
utomatic injectable) (EpiPen, Dey, L.P., Napa,
alifornia). The risk of anaphylactoid reaction with
UCA appears equal to or lower than that associ-
ted with low osmolar noniodinated radiocontrast
edia (17); individuals with a history of atopy, such
s drug, food, or environmental allergy, may be at
omewhat higher risk of these reactions with both
CAs and radiocontrast agents (17).
Although it is always easiest (and safest) to
onclude that “further studies are warranted,” it is
nlikely that additional investigation will signifi-
antly alter our current understanding of UCA
afety. We now know that UCAs are safe by
ny reasonable standard, including use in hospital-
zed patients (4,6,7–10) and ambulatory outpatients
7–12), as well as in patients undergoing rest (4,6–9)
r stress echocardiography (7–12,14), and certainly are
afe in comparison with competing/complementary
ardiovascular testing modalities including coronary
ngiography, transesophageal echocardiography,
uclear imaging, and physical or pharmacologic
tress testing (2). When considered in association
ith professional society recommendations (13,14),
s well as recent efficacy data published in American
ollege of Cardiology journals that have confirmed
he critical role UCAs play in enhancing the accu-
acy of stress echocardiography (18) and in improv-
ng the diagnostic utility of transthoracic echocar-
iography in patients with suboptimal baseline
maging (19), the benefit-to-risk calculation for
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1059ontrast echocardiography strongly supports routine
se of UCAs in all difficult to image patients.
With these substantial data in support of safety
nd efficacy, the time is right for the FDA to lift the
lack box warning, withdraw the disease state
arnings, and rescind the 30-min monitoring pe-
iod after contrast injection, all of which discourage
CA use in the patients most likely to derive thetrast agent: multicenter registry results Emergency Physiciangraphy. In 2007, the FDA questioned the safety of
CAs based on anecdote. These questions have
ow been answered—with evidence.
eprint requests and correspondence: Dr. Michael L.
ain, Cardiovascular Consultants, 4330 Wornall Road,
uite 2000, Kansas City, Missouri 64111. E-mail:reatest benefit from contrast-enhanced echocardi- mmain@cc-pc.com.1
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